Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

I've had a stoma, I've had one toilet that's been completely accessible for me," says Emma Sellars. "It is a real downer to ...

Castor oil packs promise to relieve bloating and pain, and make skin glow. But is this messy DIY practice a real benefit?

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

REYKJAVIK, Iceland and PARSIPPANY, NJ, USA I1, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.